4/A: Guided Therapeutics Director John Imhoff Significantly Boosts Common Stock Holdings Through Conversions and Acquisitions

John E. Imhoff, a Director and 10% Owner of Guided Therapeutics Inc. (GTHP), reported a substantial increase in his direct beneficial ownership of common stock through a series of preferred stock conversions and new acquisitions in March and April 2025.

Summary

• John E. Imhoff, a Director and 10% Owner of Guided Therapeutics Inc. (GTHP), filed an amended Form 4 detailing multiple transactions that significantly increased his common stock holdings.
• On March 6, 2025, Mr. Imhoff converted 300 shares of Series D preferred stock (stated value $750, $0.25 exercise price) into 900,000 shares of common stock.
• Also on March 6, 2025, he converted 2,400.75 shares of Series C2 preferred stock (at a $0.50 conversion price) into 4,801,500 common shares.
• On March 7, 2025, Mr. Imhoff purchased 286 shares of Series C preferred stock from a third party for $112,934.50, which were subsequently converted on March 11, 2025, into 2,258,690 common shares at a conversion price of $0.1266.
• On March 13, 2025, he purchased 150 shares of Series E preferred stock from a third party for $30,000, with these shares having a stated value of $1,000 and a conversion price of $0.25.
• On March 18, 2025, Mr. Imhoff acquired 1,000,000 common shares at $0.1 per share and 1,000,000 warrants with an exercise price of $0.13, expiring on March 17, 2029.
• Also on March 18, 2025, he exchanged a $25,000 note payable and $1,307 in accrued interest for 263,069 common shares at $0.1 per share, and received an additional 263,069 warrants with an exercise price of $0.13, expiring on March 17, 2029.
• On April 10, 2025, 6,365 common shares were issued to Mr. Imhoff as payment for accrued dividends on his Series F preferred stock, at a conversion price of $0.0943.
• Following these transactions, Mr. Imhoff's direct beneficial ownership of common stock increased to 17,992,380 shares, and his direct beneficial ownership of warrants increased to 1,263,069.

Sentiment

Score: 8

Explanation: The sentiment is highly positive as a key insider, who is also a 10% owner and director, has significantly increased their direct beneficial ownership of common stock through various conversions and acquisitions. This demonstrates strong confidence in the company's future performance and aligns management's interests with shareholders.

Positives

• The significant increase in common stock ownership by a Director and 10% Owner, John E. Imhoff, indicates strong insider confidence in the company's future prospects.
• The conversion of preferred stock into common stock simplifies the capital structure for the shares involved and aligns the insider's interests more directly with common shareholders.
• The acquisition of additional common shares and warrants through various means, including conversion of debt and dividend payments, demonstrates continued investment and commitment from a key insider.

Future Outlook

N/A

Industry Context

This filing is a standard disclosure of insider transactions and does not provide broader industry context. However, significant insider buying or conversions can be interpreted by the market as a positive signal regarding the company's internal outlook.

Stakeholder Impact

• Shareholders: May view the increased insider ownership as a positive signal of confidence from a key director and 10% owner, potentially leading to increased investor confidence and positive share price movement.
• Management: The transactions further align the financial interests of John E. Imhoff with the long-term performance of the company's common stock.

Key Dates

Keywords

Guided Therapeutics, GTHP, Insider Trading, Form 4, Beneficial Ownership, Stock Conversion, Preferred Stock, Common Stock, Warrants, John E. Imhoff